Riociguat Patent Expiration

Riociguat is used for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) to improve exercise capacity and WHO functional class, and delay clinical worsening. It was first introduced by Bayer Healthcare Pharmaceuticals Inc in its drug Adempas on Oct 8, 2013. 2 different companies have introduced drugs containing Riociguat.


Riociguat Patents

Given below is the list of patents protecting Riociguat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Adempas US10662188 Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate Feb 18, 2034 Bayer Hlthcare
Adempas US11203593 Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate Feb 18, 2034 Bayer Hlthcare
Adempas US7173037 Carbamate-substituted pyrazolopyridines Dec 04, 2026 Bayer Hlthcare
Adempas US6743798 Substituted pyrazole derivatives condensed with six-membered heterocyclic rings Jul 16, 2019

(Expired)

Bayer Hlthcare



Riociguat's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Riociguat Generic API Manufacturers

Several generic applications have been filed for Riociguat.

Given below is the list of companies who have filed for Riociguat generic, along with the locations of their manufacturing plants worldwide.


1. MSN

Msn Laboratories Private Ltd has filed for 5 different strengths of generic version for Riociguat. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG

tablet Prescription ORAL AB Sep 1, 2022
1MG

tablet Prescription ORAL AB Sep 1, 2022
1.5MG

tablet Prescription ORAL AB Sep 1, 2022
2MG

tablet Prescription ORAL AB Sep 1, 2022
2.5MG

tablet Prescription ORAL AB Sep 1, 2022


Manufacturing Plant Locations
New

Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.

Country City Firm Name
India
Yadadri Bhuvanagiri District MSN Organics Private Limited
Medak MSN LIFE SCIENCES PRIVATE LIMITED
Sangareddy MSN Laboratories Private Ltd.
Rangareddy District MSN Laboratories Private Limited
Isnapur MSN Laboratories Private Limited, Unit-II
Jinnaram, Sangareddy MSN Laboratories Private Limited - Formulations Division
Rangareddy District MSN Laboratories Private Limited (Formulations Division, Unit-II)
Sangareddy MSN Laboratories Private Limited, R&D Center
Sangareddy MSN Pharmachem Private Limited
Kamareddy MSN Life Sciences Private Limited
United States
Piscataway MSN PHARMACEUTICALS INC